CRISPR THERAPTC (NASDAQ:CRSP) traded up 8% on Friday after the company announced better than expected quarterly earnings. The stock traded as high as $19.94 and last traded at $19.22, with a volume of 577,867 shares. The stock had previously closed at $17.80.
The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.06. CRISPR THERAPTC had a negative return on equity of 53.86% and a negative net margin of 406.61%. The firm had revenue of $3.60 million during the quarter, compared to the consensus estimate of $3.29 million. CRISPR THERAPTC’s revenue was up 350.0% compared to the same quarter last year.
Several equities analysts have recently weighed in on the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of CRISPR THERAPTC in a report on Tuesday, July 18th. Cann assumed coverage on CRISPR THERAPTC in a report on Monday, July 17th. They set a “market perform” rating for the company. Finally, SunTrust Banks, Inc. started coverage on CRISPR THERAPTC in a report on Thursday, July 13th. They set a “hold” rating and a $16.00 price target for the company. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $21.92.
In related news, Director Kurt Von Emster sold 81,435 shares of CRISPR THERAPTC stock in a transaction dated Tuesday, June 27th. The stock was sold at an average price of $17.08, for a total value of $1,390,909.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Rodger Novak sold 30,222 shares of CRISPR THERAPTC stock in a transaction dated Wednesday, June 21st. The stock was sold at an average price of $15.01, for a total value of $453,632.22. Following the completion of the sale, the chief executive officer now owns 1,230,397 shares of the company’s stock, valued at $18,468,258.97. The disclosure for this sale can be found here. Insiders sold a total of 543,814 shares of company stock valued at $9,232,047 over the last quarter. 39.98% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the stock. IHT Wealth Management LLC purchased a new stake in CRISPR THERAPTC during the first quarter worth about $110,000. Monashee Investment Management LLC increased its stake in CRISPR THERAPTC by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock worth $473,000 after buying an additional 15,000 shares in the last quarter. Paulson & CO. Inc. purchased a new stake in CRISPR THERAPTC during the first quarter worth about $1,099,000. Wellington Management Group LLP increased its stake in CRISPR THERAPTC by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock worth $16,272,000 after buying an additional 3,070 shares in the last quarter. Finally, ARK Investment Management LLC purchased a new stake in CRISPR THERAPTC during the second quarter worth about $206,000. Institutional investors and hedge funds own 24.08% of the company’s stock.
The stock’s 50 day moving average price is $17.08 and its 200-day moving average price is $17.49. The stock’s market capitalization is $768.74 million.
WARNING: This news story was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.com-unik.info/2017/08/12/crispr-theraptc-nasdaqcrsp-shares-up-8-following-earnings-beat.html.
About CRISPR THERAPTC
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
What are top analysts saying about CRISPR THERAPTC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CRISPR THERAPTC and related companies.